Goldman Jonathan 4
4 · Avalo Therapeutics, Inc. · Filed Nov 17, 2025
Insider Transaction Report
Form 4
Goldman Jonathan
Director
Transactions
- Sale
Common Stock
2025-11-14$14.30/sh−3,167$45,288→ 0 total - Exercise/Conversion
Common Stock
2025-11-14$9.88/sh+8,200$81,016→ 8,200 total - Sale
Common Stock
2025-11-14$14.35/sh−8,200$117,649→ 0 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-11-14−8,200→ 16,400 totalExercise: $9.88Exp: 2034-08-13→ Common Stock (8,200 underlying)
Footnotes (2)
- [F1]The reported securities were sold in multiple transactions at prices ranging from $14.02 to $14.60. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
- [F2]The stock option vests 1/3 on March 28, 2025, March 28, 2026 and March 28, 2027, subject to the Eligible Director's continued service on such vesting date.